Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease
(RTTNews) - Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.
PRX-102 is a novel recombinant human a-Galactosidase-A (a-Gal-A) enzyme being investigated as an enzyme replacement therapy (ERT) for the treatment of Fabry disease.
The positive CHMP opinion was based on a marketing authorization application (MAA) that includes positive data from a comprehensive set of preclinical, clinical and manufacturing studies evaluating PRX-102.
The CHMP opinion is now referred for final action to the European Commission (EC). A final EC decision on the MAA is expected in the beginning of May 2023.
Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman
Protalix Resubmits To FDA The BLA For Pegunigalsidase Alfa For Treatment Of Fabry Disease
Major European Markets Close Slightly Weak
TSX Marches On, Hits Fresh Record High; Materials Stocks Rally
Bank Of Japan Holds Rate Steady; Plans To Lower ETF Holdings
Bay Street Likely To Open On Subdued Note
FTSE 100 Recovers After Slight Setback, Up Marginally At Noon
